Iridex Stock Gains After Posting Highest Sales Since 2007
- Iridex Corporation (NASDAQ: IRIX) reported Q2 revenue of $13.4 million, the highest since 2007, +116% Y/Y, beating the consensus of $11.61 million.
- Cyclo G6 product family generated sales of $3.6 million, +70% Y/Y on 16,000 probes sold, up 103% Y/Y.
- Iridex sold 47 Cyclo G6 Glaucoma Laser Systems, compared to 42 a year ago.
- Retina product revenue nearly tripled to $7.6 million, with 28% from PASCAL products acquired from Topcon.
- Gross margin expanded from 38.7% to 45.5%, primarily attributable to the impact of production efficiency initiatives, greater overhead absorption, and increase in higher-margin probes.
- The Company reported Q2 EPS of $0.09, a turnaround from EPS loss of $(0.20), ahead of Wall Street estimate of $(0.20).
- Iridex ended Q2 with a cash balance of $26.3 million.
- FY21 Guidance: Iridex forecasts FY21 revenue of $50 million - $52 million, +38% - 43% Y/Y. Earlier sales guidance was $48 million - $51 million.
- Cyclo G6 probe sales are expected to increase to 58,000 - 60,000 from prior guidance of 56,000 - 59,000.
- Glaucoma Laser System sales expectation remains unchanged at 250 - 275.
- Price Action: IRIX shares are up 8.33% at $7.15 during the market session on the last check Friday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Earnings Long Ideas News Guidance Health Care Movers Trading Ideas General
